Posted inClinical Updates news Respiratory
Ivermectin for COVID-19: From Pandemic Controversy to Definitive Futility in the REMAP-CAP and Global Randomized Trials
A comprehensive evidence-based synthesis of the REMAP-CAP trial and major international RCTs, demonstrating that ivermectin fails to improve clinical outcomes, survival, or organ support requirements in hospitalized and non-hospitalized COVID-19 patients.